DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for X-linked adrenal hypoplasia congenita — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleX-linked adrenal hypoplasia congenita maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for x-linked adrenal hypoplasia congenita is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 0 group B member 1 (NR0B1) — NR0B1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4RWV · 1.859 Å · ligand (2S)-3-{[(R)-{[(1S,2S,3R,4S,5S,6S)-2,6-dihydroxy-3,4,5-tris(phosphonooxy)cyclohexyl]oxy}(hydroxy)phosphoryl]oxy}propane
-1,2-diyl dihexadecanoate (PIZ). Experimental structure, not a prediction.
What the evidence adds up to
X-linked adrenal hypoplasia congenita is caused by mutations in DAX-1 (NR0B1), a gene that plays a key role in adrenal and reproductive development. A 2017 case report describes a 2.5-year-old boy who presented with acute adrenal failure; family history revealed unexplained death in three brothers of the patient's mother during infancy. Molecular analysis identified a novel hemizygous mutation, c.870C>A in exon 1, leading to a premature stop codon. The same mutation was found in the patient's mother. The truncated mutant protein is most likely misfolded, sequestered in the endoplasmic reticulum, and cannot bind to or activate its target DNA sequences in the nucleus.
No drug treatment for X-linked adrenal hypoplasia congenita is tested or reported in these abstracts. The 2010 review discusses antenatal dexamethasone for a different disease, congenital adrenal hyperplasia (CAH), which is caused by a defect in cortisol synthesis enzymes, most often 21-hydroxylase. That review states dexamethasone has been shown to prevent virilisation of affected girls, but also notes that some researchers have reported adverse effects of antenatal treatment, and that no firm conclusions about potential risks have been reached. The 1973 abstract is a placeholder with no data.
What is missing for X-linked adrenal hypoplasia congenita specifically: no clinical trial of any drug, no animal model data for a therapeutic agent, no evidence of any intervention that alters the course of the disease. The only molecular finding is a single novel mutation in one family. There is no patient stratification, no funding for a trial, and no proposed drug mechanism to test.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractUNLABELLED: Congenital adrenal hyperplasia (CAH) is caused by a defect in any of the 5 enzymes necessary for the synthesis of cortisol. However, in more than 90% of cases, CAH results from a defect in the enzyme 21-hydroxylase. Antenatal dexamethasone for the treatment of fetuses with CAH was introduced in 1978, and has been shown to prevent virilizaton of affected girls. Some researchers have been concerned about the possible long-term side effects of this therapy. A variety of studies have evaluated cognition and behavioral traits as well as metabolic alterations in treated children and in animals, and some investigators have reported adverse effects of antenatal treatment, but no firm conclusions about the potential risks of dexamethasone have been reached. This review summarizes the outcomes of affected children with and without antenatal dexamethasone treatment, and evaluates the benefits of prenatal treatment as well as the potential risks. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader should be able to recall the pathophysiology, broad clinical presentation, differences in prognosis with and without antenatal treatment, and face the importance of the antenatal dexamethasone treatment in congenital adrenal hyperplasia despite the potential adverse effects.
American Journal of Clinical Pathology · 1973 · 2 citations
Adrenal Hypoplasia
AbstractAdrenal Hypoplasia Get access Glenn C. Szalay, M.D. Glenn C. Szalay, M.D. Southern California Perrnanente Medical Group Harbor City, California 90710 Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 59, Issue 1, 1 January 1973, Page 120, https://doi.org/10.1093/ajcp/59.1.120 Published: 01 January 1973
Journal of Pediatric Endocrinology and Metabolism · 2017 · 2 citations · open access
A novel DAX-1 (NR0B1) mutation in a boy with X-linked adrenal hypoplasia congenita
AbstractBACKGROUND: X-linked adrenal hypoplasia congenita (AHC) is caused by mutations in DAX-1 (NR0B1) playing a key role in adrenal and reproductive development. CASE PRESENTATION: Herein we report a 2.5-year-old boy who presented with acute adrenal failure. Family history revealed unexplained death in three brothers of the patient's mother during infancy. Molecular analysis of the DAX-1 gene revealed the presence of a novel hemizygous mutation, c.870C>A in exon 1, leading to the formation of a premature stop codon. The same mutation was identified in the patient's mother. The truncated mutant protein is most likely misfolded, sequestered in the endoplasmic reticulum and therefore cannot bind to and activate its target DNA sequences in the nucleus. CONCLUSIONS: DAX-1 mutation must be considered when diagnosis of primary adrenocortical insufficiency is made, especially if there is a history of unexplained death of maternal male relatives.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
